IntegraGen specializes in researching and identifying genetic biomarkers, primarily in the field of oncology. The group offers high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups. France accounts for 84.4% of net sales.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
08/09/26	€0.2180	+22.13%	100,286
07/09/26	€0.1785	-0.28%	4,501
04/09/26	€0.1790	0.00%	3,804
03/09/26	€0.1790	0.00%	201
02/09/26	€0.1790	0.00%	2,101

Real-time Euronext Paris

More quotes

Market Closed - Euronext Paris 19:55:00 08/09/2026 +04			5-day change	1st Jan Change
0.2180 ^EUR	+22.13%		+21.79%	+63.91%

06-16	IntegraGen Enters Receivership Proceedings
05-28	IntegraGen to file for court-ordered receivership

Market Cap	881K 1.02M 828K 756K 1.41M 97.09M 1.42M 9.82M 3.8M 49.63M 3.85M 3.76M 158M	P/E 2019	-23x	P/E 2020	-36.6x
Enterprise Value	-2.23M -2.59M -2.1M -1.91M -3.57M -246M -3.59M -24.84M -9.61M -126M -9.73M -9.52M -400M	EV / Sales 2019	0.49x	EV / Sales 2020	1.17x
Free-Float	32.13%	Yield 2019 *	-	Yield 2020	-

Markets		Quality
Euronext Paris	ALINT	Real-time
Börse Stuttgart	7N8	Delayed

06-16	IntegraGen Enters Receivership Proceedings
05-28	IntegraGen to file for court-ordered receivership
04-24	SSH Communications Security, Intragen Enter European Data Sovereignty Partnership	MT
04-23	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/10/25	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
02/07/25	IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025	CI
02/07/25	IntegraGen SA Reports Sales Results for the First Half of 2025	CI
29/04/25	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
15/01/25	IntegraGen SA Announces Unaudited Revenue Results for the Year 2024	CI
18/10/24	IntegraGen: losses reduced, share price soars
30/07/24	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
18/07/24	IntegraGen Reports Sales Results for the First-Half of 2024	CI
01/05/24	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

IntegraGen Stock

Stocks

ALINT

FR0010908723

Biotechnology & Medical Research

Valuation : IntegraGen

Chart: IntegraGen

Latest news : IntegraGen

Press Releases : IntegraGen

News in other languages : IntegraGen

Quotes and Performance

Price Extremes

Managers and Directors : IntegraGen

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

02/07/25	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	PU
02/07/25	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	BU
29/04/25	IntegraGen: 2024 Annual Results	BU
15/01/25	IntegraGen : Inside Information / Information on annual revenues	PU
15/01/25	IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m	BU

06-16	Bourse : tensions entre Unicredit et l'Allemagne, SpaceX flambe (encore), Bénéteau au régime
06-16	IntegraGen en procédure de redressement judiciaire
06-16	Le marché remet sa cape d'invincibilité
06-16	IntegraGen convertit sa procédure de sauvegarde en redressement judiciaire
06-15	IntegraGen annonce la conversion de sa procédure de sauvegarde en redressement judiciaire afin de poursuivre les discussions engagées avec des acteurs intéressés par ses activités

1 day	+22.13%
1 week	+21.79%
Current month	+21.45%
1 month	+31.33%
3 months	+9.00%
6 months	+21.45%
Current year	+63.91%

1 week	0.18	0.22
1 month	0.16	0.22
Current year	0.12	0.36
1 year	0.12	0.36
3 years	0.12	1.4
5 years	0.12	2.04
10 years	0.12	4.29

Manager	Title	Age	Since
Bernard Courtieu CEO	Chief Executive Officer	62	09/11/2009
Virginie de Coster DFI	Director of Finance/CFO	-	01/01/2023
Berengere Genin COO	Chief Operating Officer	-	01/01/2024

Director	Title	Age	Since
Bernard Courtieu CHM	Chairman	62	22/09/2011
Jean-Pol Detiffe BRD	Director/Board Member	53	01/01/2021
François Blondel BRD	Director/Board Member	63	31/12/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTEGRAGEN	+22.13%	+21.79%	-20.15%	-83.04%	1.37M
IOVANCE BIOTHERAPEUTICS, INC.	-1.02%	+5.07%	+265.55%	+46.22%	3.98B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+0.25%	0.00%	+94.10%	+305.67%	3.87B
VERACYTE, INC.	-0.19%	-2.26%	+30.78%	+72.00%	3.42B
CAREDX, INC.	-1.12%	+2.74%	+277.14%	+515.79%	2.63B
BGI GENOMICS CO., LTD.	+1.14%	-3.64%	-29.83%	-28.95%	2.11B
FREENOME, INC.	-3.49%	+6.95%	+54.60%	-	1.75B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-1.78%	-1.51%	+194.67%	-33.61%	1.09B
SEEGENE, INC.	+0.16%	-4.70%	+21.90%	+41.35%	1.06B
CURIOX BIOSYSTEMS CO., LTD	-5.13%	-6.05%	+5.71%	+53.92%	648M
Average	+1.09%	+2.70%	+89.45%	+98.82%	2.06B
Weighted average by Cap.	-0.75%	+0.82%	+122.92%	+156.93%

	2019	2020
Net sales	8.28M 9.63M 7.79M 7.11M 13.27M 913M 13.33M 92.3M 35.71M 467M 36.16M 35.37M 1.48B	9M 10.47M 8.47M 7.73M 14.42M 992M 14.49M 100M 38.81M 507M 39.31M 38.45M 1.61B
Net income	-285K -331K -268K -245K -456K -31.41M -459K -3.18M -1.23M -16.05M -1.24M -1.22M -51.08M	-375K -436K -353K -322K -601K -41.35M -604K -4.18M -1.62M -21.13M -1.64M -1.6M -67.25M
Net Debt	-2.52M -2.93M -2.37M -2.16M -4.04M -278M -4.06M -28.08M -10.86M -142M -11M -10.76M -452M	-3.11M -3.62M -2.92M -2.67M -4.98M -343M -5.01M -34.66M -13.41M -175M -13.58M -13.28M -558M